Clinical scenarios warranting consideration of GLP-1 therapy include: Type 2 diabetes management : Per ADA 2024 Standards of Care, GLP-1 RAs may be considered as initial therapy in patients with established atherosclerotic cardiovascular disease (ASCVD), high ASCVD risk, chronic kidney disease (CKD), or heart failure, or as add-on therapy when glycemic targets aren't met Established cardiovascular disease : Several GLP-1 receptor agonists have demonstrated cardiovascular risk reduction in patients with type 2 diabetes and established ASCVD Chronic kidney disease : While SGLT2 inhibitors are generally prioritized for CKD with type 2 diabetes when eGFR allows, GLP-1 RAs may provide complementary benefits Obesity with complications : When lifestyle interventions produce insufficient weight loss in patients with obesity-related comorbidities Important safety considerations include: Contraindications : Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
Retrieved from Zipursky, J
Strategies for weight loss with GLP-1s: For those considering or currently using GLP-1 medications, here are several strategies that can enhance their effectiveness while minimizing side effects
2013;10:e1001403
Despite the increasing prevalence of obesity worldwide, effective long-term treatments remain a challenge [2]
The Question of Thyroid Cancer The warning in patient leaflets regarding thyroid C-cell tumours stems from early rodent studies
